From gene transfer to gene therapy in lysosomal storage diseases affecting the central nervous system

Annals of Medicine
L Poenaru

Abstract

Gene transfer into the central nervous system (CNS) is one of the foremost scientific challenges today. To give a brief survey of possible approaches to gene therapy in diseases affecting the CNS, we have selected the lysosomal storage diseases (LDS), which are an excellent model of both early-onset infantile neurological forms and late-onset adult psychiatric forms. Lysosomal storage diseases represent a group of about 50 monogenic metabolic disorders resulting from a deficiency in intralysosomal enzymes involved in macromolecule catabolism. The clinical severity, including neuropsychiatric symptoms, and the absence of an efficient therapy for the majority of these disorders prompted the various trials of gene therapy now in progress. Most of the genes encoding the normal lysosomal enzymes have been cloned, and the size of the corresponding cDNAs is generally compatible with their transfer by recombinant vectors. New vectors with improved immunogenicity, transduction efficacy, insert capacity, and specificity of targeting are under development. Here we discuss several gene therapy strategies for the correction of LSD-induced anomalies in the CNS. Interesting results have been obtained by animal model brain, which raises hopes ...Continue Reading

References

Jan 1, 1991·Annual Review of Biochemistry·E F Neufeld
Jan 4, 1990·The New England Journal of Medicine·W KrivitN K Ramsay
Apr 1, 1989·The Journal of Clinical Investigation·E H BirkenmeierC J Wawrzyniak
Oct 1, 1993·The European Journal of Neuroscience·C CaillaudY Berwald-Netter
Mar 1, 1993·Nature Genetics·X O Breakefield
Mar 1, 1993·Nature Genetics·S AkliM R Peschanski
Aug 1, 1995·Molecular Biotechnology·J C GloriosoN DeLuca
Aug 1, 1995·Neuropediatrics·A EriksonJ E Månsson
Jun 11, 1996·Proceedings of the National Academy of Sciences of the United States of America·S KochanekC T Caskey
Jul 1, 1996·Nature Genetics·A Wynshaw-Boris
Aug 20, 1996·Human Gene Therapy·J C Fletcher, G Richter
Feb 10, 1997·Human Gene Therapy·K M JohnstonX O Breakefield
Mar 10, 1997·The Journal of Cell Biology·B SodeikA Helenius
Apr 17, 1998·The New England Journal of Medicine·W KrivitL A Lockman
Apr 21, 1998·The Journal of Neuropsychiatry and Clinical Neurosciences·G M MacQueenM F Mazurek
May 19, 1998·Journal of Neurovirology·M J ParrH A Fine
Jun 13, 1998·Human Gene Therapy·J S BartlettT J McCown
Jul 8, 1998·Proceedings of the National Academy of Sciences of the United States of America·M A MorsyC T Caskey
Mar 3, 1999·Proceedings of the National Academy of Sciences of the United States of America·T M DalyM S Sands
Mar 23, 1999·Nature Medicine·P R Billings

❮ Previous
Next ❯

Citations

Aug 3, 2002·CNS Drugs·Robert S Fisher, Jet Ho
Dec 7, 2007·Expert Review of Neurotherapeutics·Annamaria Vezzani
Nov 6, 2003·The American Journal of Medicine·Thomas A RatkoKarl A Matuszewski
Nov 3, 2005·Expert Opinion on Emerging Drugs·Gregory M Pastores, Natalie L Barnett
Jan 15, 2005·The Journal of Gene Medicine·N Déglon, P Hantraye

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Related Papers

Expert Opinion on Biological Therapy
J M Barranger, E A Novelli
Frontiers in Bioscience : a Journal and Virtual Library
Christoph Knosalla, David K C Cooper
Sexually Transmitted Infections
A M Lever
© 2021 Meta ULC. All rights reserved